EMA Authorised: Besremi (ropeginterferon alfa-2b) — AOP Orphan Pharmaceuticals GmbH

View source ↗

Summary

The EMA authorised Besremi (ropeginterferon alfa-2b) for the treatment of polycythemia vera; decision date 24 April 2026.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Polycythemia Vera

Drugs mentioned

• BESREMI (ropeginterferon alfa-2b)

Snippet

Status: Authorised. Therapeutic area: Polycythemia Vera. MAH: AOP Orphan Pharmaceuticals GmbH. Decision date: 24/04/2026